Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo

Journal of the National Cancer Institute

Volumn 93, Issue 1, 2001, Pages 51-56

  Freedman, Matthew ^a   San Martin, Javier ^b   O'Gorman, John ^c   Eckert, Stephen ^d   Lippman, Marc E ^e   Lo, Shih Chung B ^a   Walls, Erin L ^b   Zeng, Jianchao ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c BIOGEN   (United States)

^d Applied Logic Associates Inc   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTRADIOL; FLUORIDE; GESTAGEN; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COMPUTER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DIGITAL RADIOGRAPHY; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGY; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0035798776     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.1.51     Document Type: Article

References (34)

1. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial
2. Risk for breast cancer development determined by mammographic parenchymal pattern
3. Analysis of mammographic density and breast cancer risk from digitized mammograms
4. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian national breast screening study
5. Mammographic signs as risk factors for breast cancer
6. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: A case-control study
7. Diet, mammographic features of breast tissue, and breast cancer risk
8. Mammographic densities and risk of breast cancer
9. Mammographic features and breast cancer risk: Effects with time, age, and menopause status
10. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
11. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
12. Hormone replacement therapy and accuracy of mammographic screening
13. Effect of case selection on the performance of computer-aided detection schemes
14. Mammographic mass detection by stochastic modeling and a multi-nodular neural network
15. A study of breast parenchyma by mammography in the normal woman and those with benign and malignant disease
16. Breast masses. Mammographic and sonographic evaluation
17. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New Mexico
18. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years
19. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density
20. Mammographic breast density during hormone replacement therapy: Differences according to treatment
21. The relationship of anthropometric measures to radiological features of the breast in premenopausal women
22. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators
23. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene
24. Selective estrogen receptor modulators: An alternative to hormone replacement therapy
25. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
26. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
27. The effect of raloxifene on risk of breast cancer in post-menopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
28. Geographic differences in bone turnover: Data from a multinational study in healthy postmenopausal women
29. The quantitative analysis of mammographic densities
30. Analysis of parenchymal density on mammograms in 1353 women 25-79 years old
31. Effect of post-menopausal hormonal replacement therapy on mammographic density and parenchymal pattern
32. Mammographic density in women on postmenopausal hormone replacement therapy
33. Hormonal replacement therapy: Mammographic manifestations
34. Automated analysis of mammographic densities and breast carcinoma risk